ZNTL
Zentalis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZNTL
Zentalis Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that focused on small molecule therapeutics for cancers
Biological Technology
12/23/2014
04/03/2020
NASDAQ Stock Exchange
166
12-31
Common stock
10275 Science Center Dr., Suite 200, San Diego, California 92121
--
Zentalis Pharmaceuticals, Inc., was incorporated in Delaware on December 23, 2014 as Zeno Pharmaceuticals, Inc. Zentalis Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company dedicated to the discovery and development of clinically differentiated novel small molecule therapies targeting the underlying biological pathways of cancer.
Company Financials
EPS
ZNTL has released its 2025 Q3 earnings. EPS was reported at -0.37, versus the expected -0.51, beating expectations. The chart below visualizes how ZNTL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
